SUBSCRIBE
SUBSCRIBE

Phase 2

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Achillion Pharmaceuticals, Inc. Surges as Potential Drug Combo Seen as Hepatitis C Cure
December 22, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Second Phase Of GlaxoSmithKline’s Ebola Vaccine Delayed
December 19, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Why Gilead Sciences, Inc. And AbbVie Are Keeping An Eye On Achillion Pharmaceuticals, Inc.
December 12, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Merck & Co.,NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain
December 11, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Bristol-Myers Squibb Company, Merck & Co. Drugs Effective In Hodgkin Lymphoma Trials
December 8, 2014
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
OncoSec Medical Inc. Says ImmunoPulse Tumor Drug Met Phase II Endpoints
December 5, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
FDA Lifts Clinical Hold On Flexion Therapeutics’s FX006 For Osteoarthritis Pain
December 2, 2014
 · 
2 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Drug Development
Novartis AG Fires Scientist Who Falsified Data In 6 Research Papers
November 25, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
NeoStem, Inc.'s Stem Cell Therapy Fails Mid-Stage Heart Attack Study
November 18, 2014
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Puma Biotechnology’s Cancer Drug Neratinib Fails Mid-Stage Study
November 14, 2014
 · 
2 min read
Load More
PRESS RELEASES
Press Releases
InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren’s Syndrome in China
May 8, 2026
 · 
3 min read
Press Releases
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
May 8, 2026
 · 
12 min read
Press Releases
Beacon Therapeutics Announces Positive 12-Month Safety and Efficacy Update from Phase 2 DAWN Trial of laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2026 Annual Meeting
May 8, 2026
 · 
6 min read
Press Releases
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease
May 8, 2026
 · 
8 min read
Press Releases
Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment
May 7, 2026
 · 
3 min read
Press Releases
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 7, 2026
 · 
12 min read
Press Releases
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA
May 7, 2026
 · 
8 min read
Press Releases
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
May 7, 2026
 · 
6 min read
Press Releases
Cardiol Therapeutics’ Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
May 7, 2026
 · 
7 min read
Press Releases
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
 · 
5 min read
Press Releases
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
May 7, 2026
 · 
15 min read
Press Releases
PHERGain and PHERGain-2 advance therapeutic de-escalation in early HER2-positive breast cancer in selected patients
May 7, 2026
 · 
5 min read
Press Releases
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
 · 
18 min read
Press Releases
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
May 7, 2026
 · 
7 min read
Press Releases
Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026
May 7, 2026
 · 
1 min read
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Press Releases
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
 · 
10 min read
Press Releases
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
 · 
12 min read
Load More